Neuvivo Submits NDA to FDA for NP001, a Potential Breakthrough ALS Treatment
Key Insights
Neuvivo (search) has submitted a New Drug Application (NDA) to the FDA for NP001 (sodium chlorite infusion) for treating amyotrophic lateral sclerosis (search) (ALS (search)).
NP001 is a novel investigational immunotherapy designed to restore balance within the innate immune system, potentially slowing ALS (search) progression.
If approved, NP001 could be the first disease-modifying therapy for ALS (search) that preserves lung function and extends overall survival by up to a year.
Neuvivo (search), a biopharmaceutical company, has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for NP001 (sodium chlorite infusion) as a treatment for amyotrophic lateral sclerosis (search) (ALS (search)). This submission marks a significant step forward in the potential treatment of ALS, a progressive neurodegenerative disease with limited therapeutic options.
NP001: A Novel Immunotherapeutic Approach
NP001 is an investigational therapy designed to address ALS (search) from an immunological perspective, differentiating it from existing neurological approaches. The drug aims to restore balance within the body’s innate immune system, which is often dysregulated in ALS patients. By modulating the inflammatory processes, NP001 may slow the progression of ALS and preserve skeletal muscle function, including the diaphragm.
Unmet Needs in ALS Treatment
ALS (search) affects approximately 30,000 adults in the U.S., with a lifetime risk of 1 in 300. The disease progressively impairs muscle function, affecting walking, speech, eating, and breathing. Current treatments offer limited benefits, with no medications available that preserve breathing function or extend life by more than 2-3 months. The average life expectancy post-diagnosis remains around 2-5 years, with respiratory failure being the primary cause of death.
Clinical Evidence and Potential Benefits
Neuvivo (search)'s NDA submission is supported by data from Phase 2a, Phase 2b, and overall survival studies, as well as biomarker analysis. These studies suggest that NP001 may substantially preserve lung function and extend overall survival by up to a year, particularly in patients with underlying, uncontrolled inflammation. Prior studies have also established that NP001 is generally safe and well-tolerated.
Regulatory Pathway and Designations
NP001 has been granted Orphan Drug and Fast Track Designations by the FDA, making it eligible for Accelerated Approval and Priority Review. These designations could expedite the approval process, potentially bringing this novel therapy to patients sooner. If approved, NP001 would be the first disease-modifying treatment for ALS (search) with a unique mechanism of action focused on immunomodulation.